ReviewPituitary2017
Epidemiology of acromegaly: review of population studies.
Review in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 5 syntheses or guidelines pooled it, 337 citations in OpenAlex.
- Uterine fibroids in women diagnosed with acromegaly: a systematic review.Reviews in endocrine & metabolic disorders · 2024Pooled it
- Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults.The Cochrane database of systematic reviews · 2024Pooled it
- Recurrent acromegaly: a systematic review on therapeutic approaches.BMC endocrine disorders · 2024Pooled it
- Risk of intracranial meningioma in patients with acromegaly: a systematic review.Frontiers in endocrinology · 2024Pooled it
- Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines.Pituitary · 2023Pooled it
- Comparative effectiveness of endoscopic and microscopic adenoma removal in acromegaly.Frontiers in endocrinology · 2023Trial
- Mapping of the acromegaly quality of life questionnaire to ED-5D-5L index score among patients with acromegaly.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Trial
- Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors.Journal of clinical & translational endocrinology · 2026Review
- Thymic hyperplasia in patients with acromegaly: imaging-based assessment and clinical implications.Archives of endocrinology and metabolism · 2026Article
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden.The Journal of clinical endocrinology and metabolism · 2026Article
- Article
- Changing understanding of acromegaly epidemiology and early mortality risk.The Journal of clinical endocrinology and metabolism · 2026Review
- Acromegaly diagnosis.The Journal of clinical endocrinology and metabolism · 2026Review
- Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review.Journal of endocrinological investigation · 2026Review
- Cytokeratin 5.2 expression as a predictive marker of outcome in patients with acromegaly following endoscopic transsphenoidal surgery.Pituitary · 2026Article
- The Journey of Acromegaly Towards Treatment: A Single-Center Study.Journal of personalized medicine · 2026Article
- Article
- Skin lesions in patients treated with growth hormone and those with growth hormone excess: a current overview.Frontiers in medicine · 2026Review
- Cardiomyopathy in women with acromegaly: clinical characteristics and associated factors in a Colombian multicenter registry.Frontiers in endocrinology · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly is a rare condition necessitating large population studies for the generation of reliable epidemiological data. In this review, we systematically analysed the epidemiological profile of this condition based on recently published population studies from various geographical areas. The total prevalence ranges between 2.8 and 13.7 cases per 100,000 people and the annual incidence rates range between 0.2 and 1.1 cases/100,000 people. The median age at diagnosis is in the fifth decade of life with a median diagnostic delay of 4.5-5 years. Acral enlargement and coarse facial features are the most commonly described clinical manifestations. At the time of detection, most of the tumors are macroadenomas possibly relating to diagnostic delays and posing challenges in the surgical management. Increased awareness of acromegaly amongst the medical community is of major importance aiming to reduce the adverse sequelae of late diagnosis and treatment, improve patient outcomes and, hopefully, reduce the burden on the health care system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.